HC Wainwright Reaffirms "Buy" Rating for Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $10.00 target price on the biotechnology company's stock. HC Wainwright's price target would indicate a potential upside of 58.98% from the stock's previous close. HC Wainwright also issued estimates for Aldeyra Therapeutics' Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at $0.08 EPS, FY2028 earnings at $0.48 EPS and FY2029 earnings at $1.00 EPS.

Aldeyra Therapeutics Trading Up 2.3 %

Shares of NASDAQ:ALDX traded up $0.14 on Monday, hitting $6.29. The company had a trading volume of 480,353 shares, compared to its average volume of 437,999. The stock has a 50 day moving average price of $5.56 and a 200 day moving average price of $5.41. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.92. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30). On average, sell-side analysts expect that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Aldeyra Therapeutics

Institutional investors have recently bought and sold shares of the company. State Street Corp boosted its holdings in shares of Aldeyra Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company's stock worth $5,249,000 after buying an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Aldeyra Therapeutics by 163.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock valued at $2,571,000 after acquiring an additional 295,864 shares during the period. Barclays PLC boosted its stake in Aldeyra Therapeutics by 280.1% during the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock worth $353,000 after acquiring an additional 48,313 shares in the last quarter. SG Americas Securities LLC boosted its stake in Aldeyra Therapeutics by 14.4% during the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock worth $112,000 after acquiring an additional 2,822 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in Aldeyra Therapeutics in the fourth quarter worth $234,000. Institutional investors own 59.71% of the company's stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.